Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal submucosal bevacizumab for hereditary hemorrhagic telangiectasia-related epistaxis
2009-018049-19Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hereditary hemorrhagic telangiectasia (HHT) and epistaxis comparing Bevacizumab arm with Placebo arm (2 arms). Primary endpoint: Relative difference in average daily epistaxis VAS scores. Started Nov 2010; status: completed.
02
Drugs
bevacizumab
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)epistaxis
Beyond the preview
Go deeper on 2009-018049-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-018049-19.